Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05198310 · ClinicalTrials.gov registry record · Phase 2
Study to Assess the Safety, Pharmacokinetics, and Efficacy of KPL-404 in Participants With Rheumatoid Arthritis With Inadequate Response or Intolerance to at Least One Biologic Disease-modifying Anti-rheumatic Drug or a Janus Kinase Inhibitor
A Phase 2 study, sponsored by Kiniksa Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 145
- Enrollment target
NCT05198310 is a Phase 2 study that has completed, run by Kiniksa Pharmaceuticals. The registered enrollment target is 145 participants.
The verdict
NCT05198310, a Phase 2 study, has completed, sponsored by Kiniksa Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 145 participants
- Enrollment target
Study Summary
Phase 2 study of the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and efficacy of KPL-404 in subjects with moderate to severe Rheumatoid Arthritis.
Interventions
- DRUG Placebo
- DRUG KPL-404
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 145 participants |
| Start Date | 2021-12-14 |
| Est. Completion | 2024-05-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05198310
The ClinicalTrials.gov registry entry for NCT05198310 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 145 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Kiniksa Pharmaceuticals, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT05198310 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05198310 about?
NCT05198310 is a clinical study titled "Study to Assess the Safety, Pharmacokinetics, and Efficacy of KPL-404 in Participants With Rheumatoid Arthritis With Inadequate Response or Intolerance to at Least One Biologic Disease-modifying Anti-rheumatic Drug or a Janus Kinase Inhibitor". Phase 2 study of the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and efficacy of KPL-404 in subjects with moderate to severe Rheumatoid Arthritis.
What is the current status of trial NCT05198310?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 145 participants. The study started on 2021-12-14. Estimated completion is 2024-05-06.
What interventions are being tested in trial NCT05198310?
The interventions under investigation include: Placebo (DRUG), KPL-404 (DRUG).
Who is sponsoring clinical trial NCT05198310?
This trial is sponsored by Kiniksa Pharmaceuticals, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.